Cellestia Biotech AG

Please note: The information displayed on this page might be outdated.
Cellestia Biotech AG: Cellestia Biotech AG is a privately-owned clinical-stage company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus.
The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers with no other treatment options. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets.
Sector/Industry:
Healthcare
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Immuno-Oncology, Oncology
Listing
Private
Website:
Profiles:
Address:
Hochbergerstrasse 60 C
Basel, Basel Stadt 4057
Switzerland

Company Participants at European Biotech Investor Days 2021

Michael Pascal Bauer, Dr
Cellestia Biotech AG, Chief Executive Officer
Chief Executive Officer and Board member of Cellestia Biotech AG, Basel, Switzerland. Michael is a senior drug development professional with over 20 years’ experience in the life sciences industry. He served in senior leadership positions across disciplines such as clinical and preclinical drug development, project & portfolio management, regulatory affairs and metabolism research. He has many years of experience in leading global development projects, covering the full range of drug development, from early stage preclinical through Phase I, II and III clinical development, including IND and NDA submissions. Most recent assignments were with Novartis Pharma AG, Translational Medicine Oncology, working as Senior Global Program Manager Development and Polyphor Ltd., where he served as Head of Clinical Development. Under his leadership, several new oncology drugs were brought into clinical development and reached clinical proof of concept. Michael holds a Ph.D. in Biotechnology and M.Sc. in Chemistry